This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medgenics Announces 2011 Financial Results

Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced financial results for the year ended December 31, 2011, and the filing with the U.S. Securities and Exchange Commission (“SEC”) of the Company’s Annual Report on Form 10-K. The Form 10-K includes audited annual consolidated financial statements containing the information highlighted below, as well as additional information regarding the Company. The Form 10-K is available at and at It will be mailed to shareholders on or about March 9, 2012.

2011 Financial Results

For the year ended December 31, 2011, net research and development (“R&D”) expense increased to $5.05 million from $1.53 million for the year ended December 31, 2010. This increase is due to the use of materials and sub-contractors in connection with the Phase I/II EPODURE™ clinical trial, increased expenses in developing our Factor VIII Biopump™ and preparations for the clinical trial of INFRADURE™, including the production of a GMP vector, as well as an increase in R&D personnel and patent expenses. These increases were partially offset by $0.94 million participation from the Israeli Office of the Chief Scientist (“OCS”) and a third party recorded during 2011, compared with $1.85 million participation from the OCS, a U.S. grant and a third party during 2010.

General and administrative expense for the year was $4.92 million compared with $4.41 million for 2010. The increase was largely due to legal and professional services fees in connection with Medgenics’ IPO and to stock-based compensation expense related to options granted to consultants.

Other income for 2011 was $0.00 compared with $2.58 million for 2010. Other income in 2010 reflects the excess of the recognized amount received from the third party collaboration agreement over the amount of R&D expense incurred during the period in connection with the agreement.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs